XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary
Alberta
T2P 4K9
Canada
Tel: 1-403-455-7727
Website: http://www.xortx.com/
Email: info@xortx.com
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease.
LEADERSHIP:
CEO: Allen Davidoff
CLINICAL TRIAL:
118 articles about XORTX Therapeutics Inc.
-
XORTX Files IND with US FDA
3/31/2022
XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the filing of an investigational new drug application with the Unites States Food and Drug Administration.
-
XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral InfectionCompositions and Methods for Enhancing Anti-Viral Therapies
3/23/2022
XORTX Therapeutics Inc. announces the submission of a Patent Cooperation Treaty (PCT) patent application seeking international patent protection for the patent entitled “Compositions and Methods for Enhancing Anti-Viral Therapies”.
-
XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics StudyBridging Pharmacokinetic Study Initiated
3/14/2022
XORTX Therapeutics Inc. announces that it submitted a clinical trial application with Health Canada for a XRX-OXY-101 bridging pharmacokinetics study.
-
XORTX Provides Corporate UpdateSynopsis of 2021 Achievements and Key Activities for 2022
1/31/2022
XORTX Therapeutics Inc. is pleased to take this opportunity to provide an update on the Company’s progress in 2021 and provide insights on 2022 goals.
-
XORTX Announces Appointment of Chief Technology Officer
1/20/2022
XORTX Therapeutics Inc. is pleased to announce the appointment of Dr. David MacDonald as Chief Technology Officer (CTO).
-
XORTX to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
1/10/2022
XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10th through 13th, 2022.
-
XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease• Increased Xanthine Oxidase Expression in ADPKD Kidneys •
12/21/2021
XORTX Therapeutics Inc. is pleased to announce the filing of a provisional patent based upon recent discoveries specific to polycystic kidney disease.
-
XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients
12/10/2021
XORTX Therapeutics Inc. is pleased to highlight and announce the online publication of the peer reviewed paper entitled “Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19” in the American Journal of Nephrology.
-
XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners
12/9/2021
XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announced that James Molloy, Senior Biotechnology Analyst at A.G.P./Alliance Global Partners, has initiated research coverage on XORTX.
-
XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study
12/2/2021
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), announces that it has appointed Altasciences as contract research organization (CRO) for its planned Bridging pharmacokinetic study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD) and XRx-101 for acute kidney injury associated with Coronavirus infection.
-
XORTX Therapeutics Announces Annual and Special Meeting of Shareholders
11/23/2021
XORTX Therapeutics Inc. announces that it will hold its annual and special meeting of shareholders at 11:00 a.m. (Calgary time) on Monday, December 20, 2021.
-
XORTX Therapeutics Announces Partial Exercise of Over-Allotment Option Pursuant to US Public Offering
11/9/2021
XORTX Therapeutics Inc. today announced that it has issued an additional 355,000 common shares at the public offering price of US$4.129 per share
-
XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange
11/4/2021
XORTX Therapeutics Inc. wishes to clarify that the Company’s common shares were halted on both the TSX Venture Exchange (the “ TSXV ”) and the Canadian Securities Exchange (the “ CSE ”) to finalize the de-listing procedures required on the CSE.
-
XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange
11/2/2021
XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has received final approval from the TSX Venture Exchange to list its common shares on the TSXV effective as of the open of market on November 4, 2021 under the share symbol XRTX.
-
XORTX Therapeutics Announces Closing of US$12 Million Public Offering
10/15/2021
XORTX Therapeutics Inc. announced the closing of an underwritten public offering of 2,906,000 units, with each Unit consisting of one common share, no par value, and one warrant to purchase one common share at a public offering price of US$4.13 per Unit, for aggregate gross proceeds of approximately US$12 million, prior to deducting underwriting discounts and other offering expenses.
-
XORTX to Present at the LD Micro Main Event
10/14/2021
XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the LD Micro Main Event, being held October 12 through 14, 2021.
-
XORTX Announces Results from Mount Sinai’s COVID-19 Clinical StudyEarly, High Uric Acid is Independently Associated with Acute Kidney Injury and Mortality in COVID-19
10/14/2021
XORTX Therapeutics Inc. is pleased to announce and share the results of an American Society of Nephrology Kidney Week abstract by Dr. Steven Coca and team at Mount Sinai Hospital Network and Icahn School of Medicine, that will be published online Friday, October 15, 2021
-
XORTX Therapeutics Announces Pricing of US$12 Million Public Offering and Nasdaq Listing
10/13/2021
XORTX Therapeutics Inc. announces the pricing of an underwritten public offering of 2,906,000 units ("Units"), with each Unit consisting of one common share, no par value, and one warrant ("Warrant") to purchase one common share at a public offering price of US$4.13 per unit
-
XORTX Therapeutics Announces Share Consolidation
9/20/2021
XORTX Therapeutics Inc. announces that further to its news release dated August 13, 2021 the Company will complete a share consolidation of the issued and outstanding common shares of the Company on the basis of 11.74 pre-consolidation common shares for each one post-consolidation common share, as approved at the meeting of shareholders held on September 2, 2021.
-
XORTX Therapeutics Reports Special Meeting Results
9/2/2021
XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the Company’s Special Meeting of Shareholders.